Tetrabuthylammonium

Tetrabuthylammonium

SCHEMBL223118

CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F.[O-]B([O-])F

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SLC22A1 O15245 4/20 0.67
SLC22A2 O15244 1/20 0.58
ALDH1A1 P00352 1/20 0.52
TP53 P04637 1/20 0.52
CYP3A4 P08684 1/20 0.52
ALOX15 P16050 1/20 0.52
TSHR P16473 1/20 0.52
ALOX12 P18054 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
HSD17B10 Q99714 1/20 0.52
DNM1 Q05193 6/20 0.48
LSS P48449 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tetrabuthylammonium SCHEMBL560748 1.00 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL313065 1.00 SLC22A1 (0.67) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
SCHEMBL10589857 0.95 SLC22A1 (0.65) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrahexylammonium SCHEMBL4303466 0.92 SLC22A1 (0.68) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrahexylammonium SCHEMBL14250018 0.92 SLC22A1 (0.68) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL4934836 0.88 SLC22A1 (0.75) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL3906566 0.88 SLC22A1 (0.75) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL16973025 0.88 SLC22A1 (0.75) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL7558637 0.87 SLC22A1 (0.57) SLC22A1SLC22A2ALDH1A1TP53CYP3A4
Tetrabuthylammonium SCHEMBL7970991 0.86 SLC22A1 (0.71) SLC22A1SLC22A2ALDH1A1TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240120519-A1 NON-AQUEOUS REDOX FLOW BATTERIES ENI S.P.A. (IT) 2024-04-11 US disclosed
EP-4252297-A1 NON-AQUEOUS REDOX FLOW BATTERIES ENI S.p.A. (IT) 2023-10-04 EP disclosed
WO-2022112932-A1 NON-AQUEOUS REDOX FLOW BATTERIES ENI S.P.A. (IT) 2022-06-02 WO disclosed
EP-3569624-A1 METHOD FOR THE PRODUCTION OF POLYISOCYANATES COMPRISING ISOCYANURATE GROUPS AND THEIR USE BASF SE (DE) 2019-11-20 EP disclosed
US-10428043-B2 Green oxidation catalytic system TRUSTEES OF BOSTON UNIVERSITY (US) 2019-10-01 US disclosed
EP-3498743-A1 METHOD FOR PRODUCING A PREPOLYMER CONTAINING POLYOXYMETHYLENE GROUPS Covestro Deutschland AG (DE) 2019-06-19 EP disclosed
US-20180297976-A1 GREEN OXIDATION CATALYTIC SYSTEM TRUSTEES OF BOSTON UNIVERSITY (US) 2018-10-18 US disclosed
EP-3143185-A1 METHOD FOR PRODUCING 1.5-DIAMINONAPHTHALENE AND 1-AMINO-5-NITRONAPHTHALENE BY DIRECT ELECTROCHEMICAL AMINATION OF NON-ACTIVATED OR DEACTIVATED AROMATIC SYSTEMS ON BORON-DOPED DIAMOND ANODES Covestro Deutschland AG (DE) 2017-03-22 EP disclosed
WO-2016100850-A2 GREEN OXIDATION CATALYTIC SYSTEM TRUSTEES OF BOSTON UNIVERSITY (US) 2016-06-23 WO disclosed
WO-2015173221-A1 METHOD FOR PRODUCING 1.5-DIAMINONAPHTHALENE AND 1-AMINO-5-NITRONAPHTHALENE BY DIRECT ELECTROCHEMICAL AMINATION OF NON-ACTIVATED OR DEACTIVATED AROMATIC SYSTEMS ON BORON-DOPED DIAMOND ANODES COVESTRO DEUTSCHLAND AG (DE) 2015-11-19 WO disclosed
EP-0290385-B1 PROCESS FOR PREPARING 4-ACYLOXY-3-HYDROXYETHYL-AZETIDINONES CIBA-GEIGY AG (CH) 1992-10-21 EP disclosed
EP-0382106-A2 Process for manufacturing thiophene derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1990-08-16 EP disclosed
EP-0380767-A2 Process for the adherent metallisation of highly temperature-stable plastics SCHERING AKTIENGESELLSCHAFT (DE) 1990-08-08 EP disclosed
EP-0379062-A2 Acicular magnetic iron pigments with an adjustable coercive force, and process for their production; Fe metal pigments for magnetic recording with an adjustable coercive force Studiengesellschaft Kohle mbH (DE) 1990-07-25 EP disclosed
EP-0317748-A2 Pre-treatment process for synthetic resins SCHERING AKTIENGESELLSCHAFT (DE) 1989-05-31 EP disclosed
EP-0085158-B1 PROCESS FOR THE PREPARATION OF CYCLOALKENON DERIVATIVES F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1985-06-19 EP disclosed
EP-0127216-A1 Process for the preparation of 21-hydroxy-20-keto-delta16-steroids and intermediate compounds formed in this process ROUSSEL-UCLAF (FR) 1984-12-05 EP disclosed
EP-0094563-A2 Process for the production of electrically conductive condensed aromatic compounds, products obtained thereby and their use BASF Aktiengesellschaft (DE) 1983-11-23 EP disclosed
EP-0089575-A1 Method of manufacturing conductive oligophenyls, products manufactured by this method and their use BASF Aktiengesellschaft (DE) 1983-09-28 EP disclosed
EP-0085158-A2 Process for the preparation of cycloalkenon derivatives F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1983-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428043-B2 Green oxidation catalytic system TKT, OGDH, SOD1 SLC22A1 3772/4885SLC22A2 3643/4885ALDH1A1 780/4885
US-20180297976-A1 GREEN OXIDATION CATALYTIC SYSTEM TKT, OGDH, SOD1 SLC22A1 3772/4885SLC22A2 3643/4885ALDH1A1 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.